FUTURE PLANS

For more details of our future plans, see "Business – Strategies."

USE OF PROCEEDS

We estimate that we will receive net proceeds of approximately HK$412.9 million after deducting the underwriting fees and expenses payable by us in the Global Offering, assuming no exercise of the Over-allotment Option and assuming an Offer Price of HK$22.70 per Offer Share, being the mid-point of the indicative Offer Price range of HK$20.65 to HK$24.75 per Offer Share in this Prospectus.

We intend to use the net proceeds from the Global Offering for the following purposes:

- Approximately HK$185.8 million, representing 45.0% of the net proceeds, will be used for our Core Product CU-20401:
    - Approximately HK$173.4 million, representing 42.0% of the net proceeds, will be used to fund the continuing clinical development activities as well as registration filings, post-approval studies and costs and expenses of R&D staff and activities of our Core Product CU-20401:
        - Approximately HK$76.4 million, representing 18.5% of the net proceeds, will be used in ongoing research and development of CU-20401 in the Phase II and Phase III clinical trials for submental adipose accumulation in China. We plan to initiate a Phase II clinical trial for submental adipose accumulation in July 2023 and expect to recruit approximately 120 patients and to have first patient in the third quarter of 2023. We plan to initiate a Phase III clinical trial for submental adipose accumulation in 2025 and complete primary endpoint read-out in 2027. We plan to allocate approximately HK$10.3 million, representing 2.5% of the net proceeds to the Phase II clinical trial, and approximately HK$31.0 million, representing 7.5% of the net proceeds to the Phase III clinical trial of CU-20401 for submental adipose accumulation in China, respectively. The Phase III clinical trial is expected to be designed as an MRCT in Asia, covering the jurisdictions of Hong Kong, Taiwan, Japan and South Korea.
        - Approximately HK$76.4 million, representing 18.5% of the net proceeds, will be used in ongoing research and development of CU-20401 in the Phase I, Phase II and Phase III clinical trials for abdominal adipose accumulation in China. We are actively recruiting subjects for the Phase I clinical trial and expect to complete patient enrollment in the third quarter of 2023. We plan to initiate a Phase II clinical trial for abdominal adipose accumulation in 2024 and expect to recruit approximately 150 to

200 patients and to have first patient in 2024. We plan to initiate a Phase III clinical trial for abdominal adipose accumulation in 2026. The Phase III clinical trial is expected to be designed as an MRCT in Asia, covering the jurisdictions of Hong Kong, Taiwan, Japan and South Korea.

- Approximately HK$20.6 million, representing 5.0% of the net proceeds, will be used in the registration filings of CU-20401 in China, as well as IND applications, registrations filings of CU-20401 in other jurisdictions in Asia. We plan to submit NDA of CU-20401 to the NMPA as early as 2027.

- Approximately HK$12.4 million, representing 3.0% of the net proceeds, will be used to enable the local production of CU-20401 in Mainland China. The manufacturing facilities are equipped with three production lines and our Directors believe that the facilities have a potential production capacity of one million doses for CU-20401 upon its commercialization with appropriate technical enhancement.

- Approximately HK$90.8 million, representing 22.0% of the net proceeds, will be used to fund the continuing research and development activities of our Key Products, CU-40102 and CU-10201, including the planned clinical trials and the preparation of registration filings:

  - Approximately HK$45.4 million, representing 11.0% of the net proceeds, will be used to fund the continuing clinical development activities and future milestone payments of CU-40102,

  - Approximately HK$45.4 million, representing 11.0% of the net proceeds, will be used to fund the continuing clinical development activities and future milestone payments of CU-10201,

- Approximately HK$74.3 million, representing 18.0% of the net proceeds, will be used to fund the continuing R&D activities of the other candidates in our pipeline, including the planned clinical trials and the preparation of registration filings:

  - Approximately HK$29.7 million, representing 7.2% of the net proceeds, for the R&D of CU-40101, CU-40103, CU-40104 and other potential scalp diseases and care products;

    - Approximately HK$10.7 million, representing 2.6% of the net proceeds, will be used in ongoing research and development of CU-40101 in the Phase I clinical trials. We are currently conducting a Phase I clinical trial for CU-40101. We expect to complete the Phase I clinical trial in the second quarter of 2024;

  - Approximately HK$7.4 million, representing 1.8% of the net proceeds, will be used in ongoing research and development of CU-40103 in the Phase I clinical trials. We are currently conducting the pre-clinical study of CU-40103. We plan to submit an ANDA to the NMPA in the third quarter of 2024;

  - Approximately HK$7.4 million, representing 1.8% of the net proceeds, will be used in ongoing research and development of CU-40104 in the Phase I clinical trials. We are currently conducting the pre-clinical study of CU-40104. We plan to submit an IND application to the NMPA in the fourth quarter of 2024;

  - Approximately HK$4.1 million, representing 1.0% of the net proceeds, will be used in research and development of other potential scalp diseases and care products.

- Approximately HK$29.7 million, representing 7.2% of the net proceeds, for the R&D of CU-10101, CU-10401 and other potential skin diseases and care products;

  - Approximately HK$12.4 million, representing 3.0% of the net proceeds, will be used in ongoing research and development of CU-10101 in the Phase I clinical trials. We are currently under the pre-clinical stage for CU-10101. We plan to submit an IND application to the NMPA in the second quarter of 2024;

  - Approximately HK$12.4 million, representing 3.0% of the net proceeds, will be used in ongoing research and development of CU-10401 in the Phase I clinical trials. We are currently conducting the pre-clinical study of CU-10401. We plan to submit an ANDA to the NMPA in 2026;

  - Approximately HK$5.0 million, representing 1.2% of the net proceeds, will be used in research and development of other potential skin diseases and care products.

- Approximately HK$14.9 million, representing 3.6% of the net proceeds, for the R&D of CU-30101;

  - Approximately HK$14.9 million, representing 3.6% of the net proceeds, will be used in ongoing research and development of CU-30101 in the Phase III clinical trials and its registration filings. We received the NMPA's IND approval for CU-30101 in November 2022. We initiated the Phase III clinical trial in April 2023 and plan to submit an NDA to the NMPA in 2025;

- Approximately HK$41.3 million, representing 10.0% of the net proceeds, for technology development and business development for pipeline expansion:

  - Approximately HK$20.6 million, representing 5.0% of the net proceeds, for expansion of our CATAME® platform and explore other potential innovative platform technology;

  - Approximately HK$20.6 million, representing 5.0% of the net proceeds, for strategically in-license potential market-leading and differentiated candidates with a focus in assets that fulfill market unmet needs and are complementary to our candidate portfolio. When selecting potential in-licensing arrangement targets, we will consider various factors, including (1) synergy with or complement to our existing and future products, (2) R&D geographic locations that can take advantage of our existing footprint and (3) growth potential. According to Frost & Sullivan, as of the Latest Practicable Date, there were approximately 100 companies in China and overseas markets which have assets that may be considered as potential targets for in-licensing, subject to further commercial consideration and assessment. As of the Latest Practicable Date, we had not identified any specific in-licensing targets.

- Approximately HK$20.6 million, representing 5.0% of the net proceeds, will be used for working capital and other general corporate purposes.

The above allocation of the proceeds will be adjusted on a pro rata basis in the event that the Offer Price is fixed at a higher or lower level compared to the mid-point of the estimated Offer Price range. If the Offer Price is set at HK$24.75 per Share, being the high end of the indicative Offer Price range, the net proceeds from the Global Offering will increase by approximately HK$41.7 million. If the Offer Price is set at HK$20.65 per Share, being the low end of the indicative Offer Price range, the net proceeds from the Global Offering will decrease by approximately HK$41.7 million.

If the Over-allotment Option is exercised in full, and net proceeds that we will receive will be approximately HK$482.1 million, assuming an Offer Price of HK$22.70 per Share (being the mid-point of the indicative Offer Price range). In the event that the Over-allotment Option is exercised in full, we intend to apply the additional net proceeds to the above purpose in the proportions stated above.

If the net proceeds of the Global Offering are not immediately applied to the above purposes, we will only deposit those net proceeds into short-term interest-bearing accounts at licensed commercial banks and/or other authorised financial institutions (as defined under the Securities and Futures Ordinance).